Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoablation vs TURBT in Recurrent NMIBC
NCT06781879Phase 4Recruiting
- Start
- Jun 2025
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 4, randomised, open-label trial of mitomycin c in Non-muscle-invasive bladder cancer (NMIBC) (2 arms). Primary endpoint: Recurrence Free Survival at 2 years. Started Jun 2025; status: recruiting.
02
Drugs
mitomycin c
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06781879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06781879.